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Over the past 25 years evidence based medicine has 
been increasingly used by healthcare professionals in 
the United Kingdom in the development of guidelines. 
According to Sackett et al in 1996, a “conscientious, 
explicit, and judicious use of current best evidence in 
making decisions about the care of individual patients” 
integrates clinical expertise with evidence from 
systematic research [1]. More recently Djulbegovic and 
Guyatt in 2017 suggested that evidence based medicine 
has ensured clinical medicine adopted trustworthy 
guidelines based on science and evolving methodology 
[2]. It is our view that the clinical laboratory has a 
major role in ensuring that recommendations based on 
biochemical measurements are robust. 
To illustrate this point we highlight laboratory issues 
that support the British Society for Sexual Medicine 
(BSSM) guidelines on adult onset testosterone deficiency 
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[3]. The guidelines state that men with total testosterone 
<8 nmol/l (230.74 ng/dl) or free testosterone <0.180 
nmol/l (5.19 ng/dl) usually require testosterone therapy 
(TTh) while men with total testosterone levels between 
8–12 nmol/l (230.74–346.10 ng/dl) may require TTh 
depending on the presence of symptoms associated with 
testosterone deficiency. 
The studies included in the BSSM guidelines using 
testosterone levels used to characterise or determine the 
study cohort to identify men who may benefit from TTh 
are shown in Table 1 [4–12]. Importantly, only two of the 
nine studies in Table 1 described the specific assays used 
and none provided information on assay performance 
[7, 8]. As the BSSM and other guidelines have used 
specific testosterone concentrations to identify men who 
should be considered for TTh, standardisation of the 
assays used to measure concentrations of this analyte 
together with data on assay accuracy and precision are 
essential. Further, since two of the studies stratified the 
cohorts using reference ranges [4, 9] it is also important 
that universally accepted reference ranges are used in 
comparisons of patient cohorts. Such ranges may of 
course vary between populations.
It is hoped that the programs such as that of the 
Centers for Disease Control and Prevention (CDC) 
(https://www.cdc.gov/labstandards/pdf/hs/HoSt_
Brochure.pdf - accessed 04/04/2019) and the availability 
of reference materials will help assay manufacturers and 
laboratories to standardise testosterone methods. This is 
essential if action thresholds are suggested by guidelines 
and protocols. Interestingly, Cao et al in 2017 distributed 
four samples (2 males and 2 females) to 142 accredited 
laboratories (testosterone concentrations: 15.5 ng/dl 
(0.54 nmol/l), 30 ng/dl (1.04 nmol/l), 402 ng/dl (13.94 
nmol/l) and 498ng/dl (17.27 nmol/l) and studied assay 
performance compared to target values using reference 
measurement procedures operated by the CDC reference 
laboratory [13]. It was observed that considerable bias 
existed for all the distributed samples −17.8% to 73.1%, 
3.1% to 21.3%, −24.8% to 8.6%, and −22.1% to 6.8% for 
the four samples respectively. Similarly wide variation of 
assay performance are reported by Birmingham Quality 
on behalf of the National External Quality Assessment 
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Service (NEQAS) on steroid hormones (https://
birminghamquality.org.uk/assets/doc/eqa/ster-453.pdf 
- accessed 03/04/2019) having distributed samples to 
over 200 laboratories in June 2018. The following method 
specific mean values were seen for male testosterone.
Sample A: All methods trimmed mean = 26.8 nmol/l 
(772.3 ng/dl), Abbott Architect = 29.9 nmol/l (861.7 ng/
dl), Beckman Access = 21.7 nmol/l (625.4 ng/dl), Roche 
Cobas / Modular = 27.7 nmol/l (798.3 ng/dl), Siemens 
ADVIA Centaur = 25.0 nmol/l (720.5 ng/dl), Siemens 
Immulite 2000/25000 = 23.0 nmol/l (662.8 ng/dl) and 
Tandem Mass Spectrometry = 26.1 nmol/l (752.2 ng/dl).
Sample B: All methods trimmed mean = 19.8 nmol/l 
(570.6 ng/dl), Abbott Architect = 21.5 nmol/l (619.6 ng/
dl), Beckman Access = 17.3 nmol/l (498.6 ng/dl), Roche 
Cobas / Modular = 19.8 nmol/l (570.6 ng/dl), Siemens 
ADVIA Centaur = 18.1 nmol/l (521.6 ng/dl), Siemens 
Immulite 2000/25000 = 36.8 nmol/l (1060.5 ng/dl) and 
Tandem Mass Spectrometry = 19.5 nmol/l (562.0 ng/dl).
Sample C: All methods trimmed mean = 18.9 nmol/l 
(544.7 ng/dl), Abbott Architect = 20.9 nmol/l (602.3 ng/
dl), Beckman Access = 15.6 nmol/l (449.6 ng/dl), Roche 
Cobas / Modular = 19.2 nmol/l (553.3 ng/dl), Siemens 
ADVIA Centaur = 18.2 nmol/l (524.5 ng/dl), Siemens 
Immulite 2000 / 25000 = 14.7 nmol/l (423.6 ng/dl) and 
Tandem Mass Spectrometry = 18.7 nmol/l (538.9 ng/dl). 
From this NEQAS report, only the medians / 
interquartile ranges for the Accuracy (A) score for the 
mass spectrometry and Roche Cobas assays appear to be 
within target. For the results given for the Beckman Access 
/ Dxi, the bias on one specimen reported was -40.8% 
(from the target), and between-laboratory agreement for 
the same method gave coefficients of variation at levels 
under 10 nmol/L (288.2 ng/dl) of >25%.
It is clear that considerable variation exists in 
testosterone assay performance and that publications 
often contain little information of assay performance 
which is essential in the interpretation of data from 
studies. Hence, we recommend the following measures to 
provide better healthcare with greater consistency:
•	 	Assay performance of local laboratory methods is 
made available to clinicians and bodies drawing 
up guidelines and protocols.
•	 	Data from quality assurance distribution are 
made available to bodies drawing up guidelines 
and protocols.
•	 	Laboratory personal and representatives from 
quality assurance schemes play a part in guideline 
forming committees.
•	 	Harmonisation of laboratory function regarding 
reference ranges and advice provided to clinicians 
is audited. It must be ensured that pre-analytical 
requirements and the advice provided by the 
laboratory are based on current evidence.
•	 	Greater detail of types of assays and performance 
is included in publications.
•	 	Pressure should be applied to all manufacturers 
to use international reference preparations 
(e.g. CDC) to better standardise the 
measurement of testosterone concentration to 
reduce analytical variation, analogous to the 
International Federation of Clinical Chemistry’s 
standardisation of haemoglobin A1c.
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Table 1: Studies included in the BSSM guidelines using 
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